TET2 mutation
|
MDS
|
TET2 mutation
|
MDS
|
ruxolitinib Sensitive: A2 - Guideline
|
ruxolitinib Sensitive: A2 - Guideline
|
TET2 mutation
|
AML
|
TET2 mutation
|
AML
|
azacitidine Sensitive: C2 – Inclusion Criteria
|
azacitidine Sensitive: C2 – Inclusion Criteria
|
TET2 mutation
|
MDS
|
TET2 mutation
|
MDS
|
azacitidine Sensitive: C2 – Inclusion Criteria
|
azacitidine Sensitive: C2 – Inclusion Criteria
|
TET2 mutation
|
MDS
|
TET2 mutation
|
MDS
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
TET2 mutation
|
AML
|
TET2 mutation
|
AML
|
venetoclax Sensitive: C3 – Early Trials
|
venetoclax Sensitive: C3 – Early Trials
|
TET2 mutation
|
AML
|
TET2 mutation
|
AML
|
cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials
|
cytarabine / daunorubicin liposomal formulation Resistant: C3 – Early Trials
|
TET2 mutation
|
AML
|
TET2 mutation
|
AML
|
cytarabine Sensitive: C3 – Early Trials
|
cytarabine Sensitive: C3 – Early Trials
|
TET2 mutation
|
AML
|
TET2 mutation
|
AML
|
quizartinib Sensitive: C3 – Early Trials
|
quizartinib Sensitive: C3 – Early Trials
|
TET2 mutation
|
T Cell Non-Hodgkin Lymphoma
|
TET2 mutation
|
T Cell Non-Hodgkin Lymphoma
|
lenalidomide Resistant: C3 – Early Trials
|
lenalidomide Resistant: C3 – Early Trials
|
TET2 mutation
|
Peripheral T-cell Lymphoma
|
TET2 mutation
|
Peripheral T-cell Lymphoma
|
CHOP Sensitive: C3 – Early Trials
|
CHOP Sensitive: C3 – Early Trials
|
TET2 mutation
|
MDS
|
TET2 mutation
|
MDS
|
sintilimab Sensitive: C3 – Early Trials
|
sintilimab Sensitive: C3 – Early Trials
|
TET2 mutation
|
AML
|
TET2 mutation
|
AML
|
talazoparib Sensitive: D – Preclinical
|
talazoparib Sensitive: D – Preclinical
|